{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=18", "query": { "condition": "Non-Hodgkin's Lymphoma, Relapsed", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 821, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma%2C+Relapsed&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T14:32:47.606Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01969682", "title": "A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969682" }, { "nct_id": "NCT01203020", "title": "Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 22, "start_date": "2010-10-12", "completion_date": "2021-09-27", "has_results": true, "last_update_posted_date": "2023-07-13", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01203020" }, { "nct_id": "NCT02669017", "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Burkitt's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Lymphoma, Marginal Zone", "Waldenstrom Macroglobulinemia", "Primary Mediastinal B-cell Lymphoma" ], "interventions": [ { "name": "ADCT-402", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2016-03", "completion_date": "2019-02-21", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 8, "location_summary": "La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02669017" }, { "nct_id": "NCT01956084", "title": "Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease", "Non Hodgkin Lymphoma", "Lymphoepithelioma", "Severe Chronic Active EBV Infection Syndrome (SCAEBV)", "Leiomyosarcoma" ], "interventions": [ { "name": "LMP1/2 CTLs (Group A)", "type": "DRUG" }, { "name": "LMP1/2 CTLs (Group B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catherine Bollard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10, "start_date": "2013-11", "completion_date": "2019-10-15", "has_results": false, "last_update_posted_date": "2024-12-19", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01956084" }, { "nct_id": "NCT04673617", "title": "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-03-29", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673617" }, { "nct_id": "NCT03947255", "title": "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-10-28", "completion_date": "2022-11-06", "has_results": true, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 19, "location_summary": "Anaheim, California • Lafayette, Colorado • Pembroke Pines, Florida + 14 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03947255" }, { "nct_id": "NCT00007852", "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 44, "start_date": "2000-09-01", "completion_date": "2011-01-01", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00007852" }, { "nct_id": "NCT00002348", "title": "A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Mitoguazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002348" }, { "nct_id": "NCT01660451", "title": "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (Aliqopa, BAY80-6946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2012-11-19", "completion_date": "2023-05-18", "has_results": true, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660451" }, { "nct_id": "NCT03379051", "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Ublituximab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2018-03-27", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2022-08-22", "last_synced_at": "2026-10-14T14:32:47.606Z", "location_count": 3, "location_summary": "Chicago, Illinois • Rochester, New York • Cleveland, Ohio", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03379051" } ] }